TRIAL RESULTS · SIDE EFFECTS
Ganirelix side effects
ANSWER
3 trials of Ganirelix posted side-effect results, none against placebo, so no placebo rate exists to compare. Most reported: nausea, vomiting, antepartum haemorrhage. Read from ClinicalTrials.gov on 2026-10-03. Not medical advice.
Trial register
Trials with posted results
3
with an arm on Ganirelix, of 108 registered
Against placebo
0
placebo-controlled trials
People in those trials
0
on Ganirelix · 0 on placebo
Read
2026-10-03
ClinicalTrials.gov
ALL TRIALS
All 12 side effects reported
Every trial with posted results and an arm on Ganirelix (n ≥ 20), all phases, by people affected. Placebo is shown where placebo-controlled trials reported the same event. Comparator arms are not counted.
| Side effect | Organ system | Ganirelix | Placebo | Trials |
|---|---|---|---|---|
| Nausea | Gastrointestinal disorders | 8.0% (9 of 112) | - | 1 |
| Vomiting | Gastrointestinal disorders | 5.4% (6 of 112) | - | 1 |
| Antepartum haemorrhage | Pregnancy, puerperium and perinatal conditions | 5.4% (6 of 112) | - | 1 |
| Menstruation delayed | Reproductive system and breast disorders | 9.1% (2 of 22) | - | 1 |
| Ectopic pregnancy | Pregnancy, puerperium and perinatal conditions | 1.8% (2 of 112) | - | 1 |
| Allergy to arthropod bite | Immune system disorders | 4.5% (1 of 22) | - | 1 |
| Uterine polyp | Reproductive system and breast disorders | 4.5% (1 of 22) | - | 1 |
| Abortion spontaneous | Pregnancy, puerperium and perinatal conditions | 0.9% (1 of 112) | - | 1 |
| Ovarian hyperstimulation syndrome | Reproductive system and breast disorders | 0.9% (1 of 112) | - | 1 |
| Injection site erythema | General disorders | 0.0% (0 of 22) | - | 1 |
| Mood swings | Psychiatric disorders | 0.0% (0 of 22) | - | 1 |
| Cellulitis | Infections and infestations | 0.0% (0 of 22) | - | 1 |
Source: ClinicalTrials.gov posted results, read 2026-10-03. A trial lists events above its own reporting threshold, so a rare event may be missing from some trials. Not medical advice.
REGISTERED STUDIES
108 registered clinical trials of Ganirelix
The 10 most recently updated are listed.
| NCT07732348 | Oral GnRH Antagonist (Linzagolix) Versus Injectable GnRH Antagonist in Controlled Ovarian Stimulation for In Vitro Fertilization: A Randomized Controlled Non-Inferiority Trial With a Concurrent Comparator Cohort Undergoing Progestin-Primed Ovarian Stimulation (PPOS) Status: NOT_YET_RECRUITING · Updated 2026-09-30 |
|---|---|
| NCT06745466 | Disentangling the Effects of Daily Stress, Sleep, and Sex Hormones on Accelerated Vascular Aging in Midlife Women Status: RECRUITING · Updated 2026-07-02 |
| 2023-508769-33-00 | Protocol with Progestin-primed Ovarian Stimulation (PPOS) in conventional treatment from the start of stimulation vs protocol with GnRH antagonists as a pituitary suppressor in patients who are going to undergo DUOSTIM with embryo accumulation for PGT-A of the embryos. Status: UNKNOWN · Updated 2026-05-25 |
| NCT06877429 | Is the Diurnal Variation in Circulating Levels of Cortisol Reflected in Follicular Fluid of Preovulatory Follicles Close to Ovulation? Status: NOT_YET_RECRUITING · Updated 2026-05-07 |
| NCT04983173 | INTEnsity of ovariaN Stimulation and Embryo Quality Status: COMPLETED · Updated 2026-04-14 |
| NCT05954962 | Efficacy of Micronized Natural Progesterone vs GnRH Antagonist in the Prevention of LH Peak During Ovarian Stimulation. Status: COMPLETED · Updated 2026-03-27 |
| NCT07409493 | IVF Outcomes With Time-Lapse Culture: Comparison Between PPOS and GnRH Antagonist Protocols Status: RECRUITING · Updated 2026-02-13 |
| NCT06175832 | PPOS (Progestin Primed Ovarian Stimulation) and Corifollitropin Alfa (CFA) Cross-over Study Status: RECRUITING · Updated 2025-12-26 |
| NCT05847283 | DPOS Versus GnRH Antagonist Protocol for Oocyte Accumulation in Low Ovarian Reserve Patients: An RCT Status: RECRUITING · Updated 2025-12-10 |
| NCT04166825 | Ovarian Hyperstimulation and Fibrin Clot Properties. Status: RECRUITING · Updated 2025-12-05 |
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.